Page 1210 - Basic _ Clinical Pharmacology ( PDFDrive )

1196 Index

Bone mineral homeostasis drugs (Cont.): Brentuximab vedotin, 993 Burimamide, 280
hormonal regulators, principal, 774–778 Brexpiprazole, 529t Buserelin, 676, 739
fibroblast growth factor 23, 777, 778t Brimonidine, 154t, 1078. See also Buspirone, 288–289, 383, 394t. See also
parathyroid hormone, 774f, 774–775, Sympathomimetics Serotonin (5-HT) receptor
778t Brinzolamide, 260–261, 272t agonists
PTH, FGF23, and vitamin D Brivaracetam, 422–423, 436t Busulfan, 953f, 955t. See also Alkylating
interaction in, 777–778 Brodalumab, 994 agents
vitamin D, 775–777, 776f, 777t, 778t Bromocriptine, 154t, 294, 297t, 684t. Butabarbital, 393t
hormonal regulators, secondary See also Ergot alkaloids; Butenafine, 1073
calcitonin, 778 Sympathomimetics Butorphanol, 555t, 556, 569
estrogens, 779 diabetes mellitus treated with, 764, 769t Butoxamine, 167, 170t. See also b-receptor
glucocorticoids, 779 as dopamine agonist, 679 antagonist drugs
nonhormonal regulators, 779–782 hyperprolactinemia treated with, 295 Butyrophenone derivatives, 515, 515t,
bisphosphonates, 779f, 779–781, 789t Parkinson’s disease treated with, 498, 529t
calcimimetics, 781 508t Butyrophenones, 511–524, 513f, 529t.
denosumab, 781 Brompheniramine, 283t See also Antipsychotic agents
fluoride, 781 Bronchial smooth muscle, 147 antiemetic properties of, 1105–1106
strontium ranelate, 782 Bronchodilators, 359. See also specific types structure of, 513f
thiazide diuretics, 781 Brugada syndrome, 234b Butyrylcholinesterase, 69, 132
pharmacology of, 772–773, 773f Brugia malayi, 941 cholinesterase inhibitors on, 109
preparations available, 790t Brugia timori, 941 genetic polymorphisms in, 67t, 69
vitamin D in, 773, 774f, 789t Bucindolol, 166, 170t BZ site, GABA A receptor, 386
Bopindolol, 166, 170t. See also b-receptor Budesonide. See also Corticosteroids,
antagonist drugs inhaled (aerosol) C
Borage, 1133t asthma treated with, 355, 362t C1 esterase inhibitor, 307
Bortezomib, 966t, 971 inflammatory bowel disease treated with, C6, 133–134, 134f. See also Ganglion
Bosentan. See also Endothelin inhibitors 1109 blockers
description of, 312, 313b, 317t Bulk-forming laxatives, 1098, 1117t Cabazitaxel, 963
heart failure treated with, 220 Bumetanide, for diuresis, 262t, 262–264, Cabergoline. See also Dopamine agonists;
Bosutinib, 966t, 967 273t Ergot alkaloids
Botanical pesticides, 1012–1013, 1013f Bundle branch nodal block, 234–236, 235f description of, 294, 679, 680f
Botanicals, 1131. See Herbal medications Bupivacaine, 460t, 462, 470, 472t. See also hyperprolactinemia treated with, 295
Botulinum toxin, 95 Anesthetics, local Cadmium, 1017
case study of, 89, 106 cardiotoxicity of Cadmium fume fever, 1017
spasmolytic actions of, 487 description of, 461b, 468 Caffeine
Botulinum toxin A, 131 lipid resuscitation for reversal of, 449, asthma treated with, 352–353
Botulism antitoxin heptavalent equine, 469b in OTC agents, 1129t
types A-G, 1180t historical development of, 461b structure of, 352f
Botulism immune globulin, 1180t Buprenorphine Calcifediol, 775
Botulism toxin, 1180t mixed receptor actions of, 568–569, 572t Calcimar, 783
Bradycardic drugs, 207. See also specific opioid addiction managed with, 581, Calcimimetics
drugs 588t on bone homeostasis, 781
Brain cancer, 975 properties of, 555t hyperparathyroidism treated with, 784
Brain-derived neurotrophic factor (BDNF), Bupropion Calcineurin inhibitors
533f, 533–534 adverse effects in, 547 cyclosporine, 986
Brain natriuretic peptide (BNP) chemistry of, 538f, 538–539 tacrolimus, 986
description of, 220, 308–309, 309f depression treated with, 540t, 541, 542t, Calcipotriene, 789t. See also Vitamin D
on kidney, 259 550t for bone homeostasis, 775, 777t
Breakthrough bleeding, 734 dosing, 546t psoriasis treated with, 1078–1079
Breakthroughs, drug, 11 drug interactions in, 548t, 549 Calcipotriol, 777t
Breast cancer nicotine abuse treated with, 584 Calcitonin
chemotherapy for obesity managed with, 289b on bone homeostasis, 773, 774f, 778
stage I & II, 971 pharmacodynamics of, 542t, 543 hypercalcemia treated with, 782–783,
stage III & IV, 972 pharmacokinetics of, 540t, 541 790t
from female hormonal contraceptives, poisoning/overdose of osteoporosis treated with, 787, 790t
735 seizure management in, 1035, 1047 Paget’s disease of bone treated with, 789
Breast cancer resistance protein (BCRP), 83 treatment of, 1042 Calcitonin gene-related peptide (CGRP),
Breast-feeding, 1056 preparations available, 551t 92t, 290, 314–315, 318t